Comparison of ceftriaxone and azithromycin versus amoxicillin and azithromycin for pregnant women with preterm premature rupture of membranes between 22 and 33 weeks.

Registered drugNo placebo

Comparison of ceftriaxone and azithromycin versus amoxicillin and azithromycin for pregnant women with preterm premature rupture of membranes between 22 and 33 weeks.

Registered drugNo placebo

France

Participants:18–64 years
Substances:Amoxicillin
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Craniopharyngioma

Not yet recruiting

A study to evaluate the effectiveness of semaglutide for treating obesity caused by craniopharyngioma in children aged 12 to 17 years.

Registered drug

A study to evaluate the effectiveness of semaglutide for treating obesity caused by craniopharyngioma in children aged 12 to 17 years.

Registered drug

France

Participants:0–17 years
Substances:Semaglutide
Sponsor:Centre Hospitalier Universitaire D'Angers

Contact Research Centre

Vulval cancer

Not yet recruiting

A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

Registered drugNo placebo

A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Imiquimod
Sponsor:Centre Leon Berard

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Hereditary haemochromatosis

Not yet recruiting

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Vamifeport trihydrochloride
Sponsor:CSL Behring LLC

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

TTR Amyloidosis Cardiomyopathy
Heart Failure Prevention
Cardiovascular Risk Management

02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

Head & Neck Squamous Cell Carcinoma
Gastric and GEJ Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer

03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

Frontotemporal Dementia
Essential Tremor
Traumatic Brain Injury
Multiple Sclerosis

04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

Crohn's Disease
Psoriatic Arthritis
Myasthenia Gravis
Idiopathic Pulmonary Fibrosis

Back to France All countries